| Description |
Recombinant Mouse IGFBP-3R Protein is expressed from HEK293 with hFc tag at the C-Terminus.It contains Gly39-Arg204. |
| Purity |
> 95% as determined by Tris-Bis PAGE;> 95% as determined by HPLC |
| Accession |
Q9D123 |
| Target Symbol |
IGFBP-3R |
| Synonyms |
IGFBP-3R; GFBP3R; LOC124446; TMEM219 |
| Species |
Mouse |
| Expression System |
HEK293 |
| Tag |
C-hFc |
| Expression Range |
Gly39-Arg204 |
| Mol. Weight |
The protein has a predicted MW of 44.4 kDa. Due to glycosylation, the protein migrates to 60-70 kDa based on Tris-Bis PAGE result. |
| Form |
Lyophilized |
| Formulation |
Lyophilized from 0.22um filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization. |
| Endotoxin |
Less than 1EU per ug by the LAL method. |
| Storage |
Reconstituted protein stable at -80°C for 12 months, 4°C for 1 week. Use a manual defrost freezer and avoid repeated freeze-thaw cycles. |
| Shipping |
Shipped at ambient temperature. |
| Gene Background |
Insulin-like growth factor-binding protein-3 (IGFBP-3) is a multifunctional protein known for modulating mitogenic and metabolic actions of IGFs as well as exerting a variety of biological actions not involving IGF. IGFBP-3 inhibits airway inflammation and hyper-responsiveness via an IGF-independent mechanism that involves activation of IGFBP-3R signaling and cross-talk with NF-κB signaling. The IGFBP-3/IGFBP-3R system therefore plays a pivotal role in the pathogenesis of asthma and can serve as a newly identified potential therapeutic target for this debilitating disease. |
